Proyecto de Biomedicina CIMA SL is a holding company engaged in the provision of product licensing and intellectual property rights management services. It holds patents generated by the Centro de Investigacion Medica Aplicada, which have indications across the clinical fields of oncology, hepatology, dermatology, and gene therapy. The company was founded in June 2003 and is headquartered in Pamplona, Spain.

Zibo Qidingli Patent Information Consulting Co., Ltd., established on 2013-06-03, Business scope includes patent technology consulting,to develop,to promote;advertisement plan(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)**

Jiangxi Materia Medica Technology Co., Ltd., established on 2002-12-13, Business scope includes drug research and development,Testing service;Herbal preparations,Extract,monomer(except medicines)production and sales of;biology,Manufacturing of biochemical products(Except for licenses);entrust"Guangzhou Saijian Biotechnology Co., Ltd."Production of health food"Production of Bencao Natural Wind Brand Gutianle Soft Capsules";Equipment and Vehicle Rental(except taxi business).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Cellivery’s therapeutic drug candidates are being developed for the prevention of life-threatening lethal diseases, including various cancer. The company’s subsequent drug discovery programs will focus on other diseases, in which the transient suppression of either symptoms or etiology would produce long-term benefits, that are both cost-effective and associated with a high quality of life. Cellivery Therapeutics Inc. was founded by Dr. Daewoong Jo, President and CEO in March of 2014. Its earliest notions have been prepared, however, when Dr. Jo began to study for his doctoral thesis at Vanderbilt University, Nashville, TN, USA in 1997.

Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associated infectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Youjia Hangzhou Biomedical Technology Co Ltd. is a company headquartered in China. The firm engages in research and development of nucleic acid drugs.

Nanjing Children's Hospital Ltd. is a Chinese private company located in Nanjing that provides healthcare services.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Changsha World-Way Biotech, Inc. engages in the development, production and operation of standardized plant extracts and plant-derived functional products. Its products include Macleaya Cordata Extract, Litchi Extract, Red Clover Extract, and Stevia extract. The company was founded in 2002 and is headquartered in Changsha, China.

Shanghai Zhonghua Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., is a company headquartered in Shanghai, China, that manufactures and distributes pharmaceutical products. The firm was acquired by Shanghai Pharmaceuticals Holding Co., Ltd. from Shanghai Pharmaceutical (Group) Co., Ltd. on February 03, 2010 for $27.25 million.

Tianjin Institute of Pharmaceutical Research Co., Ltd. engages in the in the development of various new products such as innovative drugs, generic drugs, new preparations, traditional Chinese medicines, and biological drugs with particular emphasis on the engineering and industrialization of new technologies to meet drug registration requirements. The company was founded in 1959 and is headquartered in Tianjin, China.

Nanjing Zhengliang Pharmaceutical Technology Co., Ltd., established on 2012-07-25, Business scope includes medical technology research and development and technical consulting;Intellectual property agency consultation;Class I medical device,Chemical Products,crafts,cosmetic,Daily necessities sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Jilin Sinopharm Pharmaceutical Co., Ltd., established on 1997-08-13, Business range includes tablet,hard capsule,Granules,pill(honey pill,honey pill,water pill,Concentrated pills),Powder production;Procurement of raw materials for own use.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Guangzhou Saliai Stemcell Science & Technology Co., Ltd. engages in the provision of stem cell storage, health supplements, biological products, and related health management services. It involves in the production of regenerative medicine devices, medical nutrition supplements, and biological & medical cosmetic products. It operates a research and development platform which includes life bank, health management center, medical center, and medical cell center. The company was founded by Hai Jia Chen and Ming Jia Chen on July 7, 2009 and is headquartered in Guangzhou, China.

HemaFlo Therapeutics, Inc. is an early stage company founded to commercialize a novel new device for the treatment of acute kidney injury and other ischemic conditions. The device is a very dilute solution of drag-reducing polymer (DRP) that is simply delivered intravenously to patients. Drag-reducing polymers have been studied in animals since the mid-1970’s and have shown dramatic benefits in disease models such as heart attack, hemorrhagic shock, diabetes, and atherosclerosis. The work has received little attention because the mechanism of action was unknown until just recently. HemaFlo Therapeutics has shown that drag-reducing polymers can be used to treat a very common and deadly condition that has a very attractive commercialization pathway. Acute kidney injury has no effective treatment and there are as many new cases in the US each year as for heart attacks, strokes, and cancer combined! Acute kidney injury is not widely perceived to be a serious problem because most cases occur in the hospital as a consequence of other diseases or procedures, resolve in a week or two, and the deaths are coded as heart failure (loss of regulation of electrolytes), respiratory failure (loss of regulation of fluids), or sepsis.

Inner Mongolia Furui Medical Science is a life science company that supplies health care. It offers disease diagnostics, medication therapy, and chronic disease management with a focus on liver disease. Tablets, capsules, and plaster are included in the company's product line. Also included in the company's activities is the provision of healthcare services.

Shenzhen Zhongke Aishen Pharmaceutical Co., Ltd., established on 2013-04-16, Business scope includes general business items:Technical development of biological products;Technology development of biotechnology products;Sales of bioengineering products and technology transfer of research and development achievements of related projects,Technical service and technical consultation.,The licensing program is: